Document is current
Any future updates will be listed below
-
Authors
Bell, R. M.
Basalay, M.
Bøtker, H. E.
Beikoghli Kalkhoran, S.
Carr, R. D.
Cunningham, J.
Davidson, S. M.
England, T. J.
Giesz, S.
Ghosh, A. K.
Golforoush, P.
Gourine, A. V.
Hausenloy, D. J.
Heusch, G.
Ibanez, B.
Kleinbongard, P.
Lecour, S.
Lukhna, K.
Ntsekhe, M.
Ovize, M.
Salama, A. D.
Vilahur, G.
Walker, J. M.
Yellon, D. M. https://orcid.org/0000-0001-7791-9320
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (CRC 1116 B8)
British Heart Foundation (PG/19/51/34493, PG/21/10798)
PGC (2018-094025-B-I00, MCIN/AEI/10.13039/501100011033)
Duke-NUS Signature Research Programme (-)
Singapore Ministry of Health’s National Medical Research Council (MOH-STaR21jun-0003)
National Research Foundation Singapore (NMRC CG21APR1006, NMRC/CG21APRC006)
- License Information
-
More Information
Article History
Received: 3 August 2022
Revised: 3 August 2022
Accepted: 3 August 2022
First Online: 15 August 2022
Declarations
:
: AVG is a founder and Chief Scientific Officer for Afferent Medical Solutions. DJH has received: consultant fees from Faraday Pharmaceuticals Inc. and Boehringer Ingelheim International GmbH; honoraria from Servier; and research funding from Astra Zeneca and Merck Sharp & Dohme Corp. All other authors have no competing interests.
